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Monoclonal antibodies have been used in the formulation of
commercially available blood grouping reagents since the early
1990s. It became apparent early on that introducing them into
routine use along with, or instead of, human- or animal-derived
reagents could and did lead to discrepant reactions. These
discrepancies most often came to light when confirming a blood
type obtained previously with human- or animal-source reagents or
when using two or more sources of a reagent from the same or
another manufacturer to perform blood typing or antibody
detection or identification testing. A number of factors contribute
to differences in reactivity of reagents that are of the same
specificity but are from more than one source. One factor is the
use of different clones of the same specificity to manufacture blood
bank reagents. Another is the effect of the various diluents used by
different manufacturers to formulate reagents that contain the same
clone(s). In addition, RBCs having unusual or rare phenotypes can
cause discrepant reactions when performing phenotyping.
Discrepant reactions can also occur because of patient or donor
antibodies that react in an unusual manner when antiglobulin tests
are performed with monoclonal antihuman globulin (AHG) versus
rabbit AHG reagent. It is important to know the identity of the
unusual or rare phenotypes and antibodies and to be able to
recognize the different types of reactions that will be observed
when using more than one reagent of the same specificity. Most
importantly, one must be able to interpret reactions correctly and
establish the true blood type of the RBCs or specificity of the
antibodies.This review will describe situations in which the use of
monoclonal reagents from more than one source or manufacturer,
or comparison with results of human- and animal-source reagents,
resulted in discrepancies with unusual or rare phenotypes or
antibodies. Many of the samples described in this review were sent
to the reference laboratory at Gamma Biologicals, Inc., in Houston,
Texas, which later became ImmucorGamma with sites in Norcross,
Georgia, and Houston, Texas. Immunohematology 2006;22:
52–63.
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For a background on the introduction of mono-
clonal antibodies as reagents to the field of blood
banking, the reader is referred to a very comprehensive
review by Marjory Stroup in a 1990 publication of
Immunohematology titled “A review: the use of
monoclonal antibodies in blood banking.”1 In addition,
two presentations by John Case, in 1992 and 1993,
provide a very good overview of monoclonal
antibodies of varying specificities used as blood bank
reagents.2,3 He also presented an excellent paper on
dealing with reagents made from human and
monoclonal Rh antibodies as the Sally Frank Lecture at
the AABB meeting in 1998, titled “Monoclonal/
polyclonal reagents. Some practical differences in
performance.”4 This present review will bring us to the
monoclonal reagents in use today in the United States
and to unusual situations involving rare blood types
and antibodies. I should point out here that even
though some of the clones used in the tube reagents
are the same as those used in the MTS gel cards
distributed by Ortho-Clinical Diagnostics, Raritan, New
Jersey, for use in the ID-Micro Typing System (Ortho-
Clinical Diagnostics), I have not included any test
results or publications on the reactions obtained with
unusual phenotypes using the gel technique,as I do not
have firsthand knowledge of how they do react.
The two most important blood group systems are
ABO and Rh. Blood samples from all blood donors,
prenatal patients, and transfusion recipients are
routinely tested for A, B, and D antigens. Some unusual
or rare phenotypes that have been found to give
discrepant or variant typing results in the ABO system
are group O with missing anti-A or anti-B in plasma, A
subgroups and rarely B subgroups, AsubgroupB and
ABsubgroup, B(A), and group A with acquired B
antigen. In the Rh blood group system, weak D, partial
D, and RhCE variants (special reference to R0
Har and
Crawford), weak C (r′s), Rh32 (RN) and others, Ew and E
variants, c variant Rh:-26, and e variants (in particular,
hrB–) have given discrepant or variant typing results. In
the Kell blood group system, K1 variants can give
different typing results depending on whether human
or certain monoclonal reagents are used. Other
monoclonal reagents that can give discrepant test
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results, when compared with tests
performed using human- or animal-source
reagents, with unusual phenotypes are 
anti-M, -N, -P1, -Lea, and -Leb. And lastly, the
monoclonal anti-IgG and anti-C3 reagents can
give varying results compared with those
obtained with rabbit antihuman globulin
(AHG) reagents when testing unusual or rare
antibodies. Throughout the paper, the reader
is referred to Table 1 for the list of clones
present in each of the monoclonal-based
reagents discussed.
ABO Reagents
To be or not to be. Is it a group O with
missing isoagglutinin, A subgroup, B
subgroup, AsubgroupB, ABsubgroup, B(A), or
group A with acquired B antigen?  These are
the questions to be answered.
During a period of four years, more than
30 samples were tested to resolve ABO
discrepancies using serologic and molecular
techniques at two independent laboratories,
the reference laboratory at ImmucorGamma
in Norcross, Georgia/Houston,Texas, and the
laboratory of Dr. Martin L. Olsson in the
University Hospital, Lund, Sweden. Many of
the samples that gave unusual ABO grouping
results were included in a paper published in
2001 by Dr. Olsson and collaborators, of
which I was one.5 Some of these samples
were tested only by serologic techniques but
most were tested by both.
One set of samples that proved to be
most interesting and diverse gave the same
serologic pattern of reactivity but different
ABO genotypes by molecular testing.
Forward grouping showed that these
samples did not react with ABO monoclonal
reagents (anti-A, -B, and -A,B) from all three
manufacturers (Immucor, Norcross, GA;
Gamma Biologicals, Inc., Houston, TX; and
Ortho-Clinical Diagnostics), suggesting the RBCs to be
group O. Yet, the serum or plasma, when tested with A
and B reagent RBCs, demonstrated expected strong
reactivity with B RBCs but lacked the expected
reactivity with A RBCs, suggesting the RBCs to be
group A. Molecular genetic analyses for ABO yielded
two patterns. In one pattern, no A allele could be
demonstrated,yet there was no explanation for the lack
of expected anti-A in the plasma. Thus, the patients and
donors were genetically group O. In the other, an A
allele was detected, indicating the patients and donors
were genetically group A, even though their RBCs did
not react with all anti-A, -B, and -A,B reagents. The
samples gave the same serologic picture but different
ABO genotyping results. This study reinforces the fact
that one should not assume either that the RBC
grouping is the correct ABO blood type or that the
Table 1. Clones used in the manufacture of reagents.
GAMMA IMMUCOR ORTHO
Tube Gel card
Clone Ig class Clone Ig class Clone Ig class Clone
Anti-A BIRMA 1 IgM BIRMA 1 IgM MH04 IgM BIRMA 1
3D3 IgM
A26A2 IgM
Anti-B GAMA110 IgM ES4 IgM NB10.5A5 IgM LB-2
NG10.3B1 IgM
B95.3 IgM NB1.19 IgM
LB–2 IgM
Anti-A,B BIRMA 1 IgM BIRMA 1 IgM MH04 IgM ES4
ES4 IgM ES4 IgM 3D3 IgM ES15
ES15 IgM ES15 IgM NB10.5A5 IgM
NB1.19 IgM
Anti-D GAMA401 IgM Series 5 MAD2 IgM MS201
TH28 IgM HUMAN IgG





Anti-C MS24 IgM MS24 IgM MS24 IgM MS24





Anti-c 951 IgM MS33 IgM MS42 IgM MS33





Anti-Lea GAMA701 IgM LM112/161 IgM LM112/161 IgM
Anti-Leb GAMA704 IgM LM129/181 IgM LM129/181 IgM
Anti-Jka MS15 IgM
Anti-Jkb MS8 IgM
Anti-K1 MS56 IgM MS56 IgM




Anti-C3b 055A.305GA IgM F7G3 IgG1
MA003
Anti-C3d 053A.714GA IgG1 C4C7 IgG1
MA004
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serum or plasma reverse grouping is the correct type.
It could be either, according to ABO genetic studies.
Several samples that were determined to be A
subgroups gave discrepant results with different anti-
A,B reagents when attempting to resolve the
discrepancy between the ABO RBC grouping and the
serum or plasma grouping. The anti-A and anti-B
reagents from all three manufacturers did not react on
forward grouping with the RBCs, suggesting that they
were group O, but the plasma of the patients and
donors on reverse grouping contained a strong
expected anti-B and lacked the expected anti-A,
suggesting that the plasma was group A. The anti-A,B
reagent from two manufacturers (Immucor and
Gamma Biologicals, Inc.), which contained a blend of
the same three clones of anti-A, anti-B, and anti-A,B, did
react with the RBCs. The anti-A,B reagent from a third
manufacturer (Ortho-Clinical), containing a blend of
two different clones of anti-A and two different anti-B
clones, did not react (Table 1). The reactivity with the
anti-A,B reagents from Immucor and Gamma was
determined to be because of the anti-A,B clone ES-15 in
the anti-A,B blended reagent. This clone has been
described as being very efficient at picking up Ax and A
subgroup RBCs.6,7
Genomic analysis was performed on samples from
three blood donors in the study that gave discrepant
serologic ABO grouping results.8 RBCs from two of the
donors reacted weakly with only one anti-A reagent
(Ortho-Clinical) and reacted strongly with all three
manufacturers’ anti-B reagents, suggesting an
AsubgroupB. The plasma of one donor contained
weakly reactive anti-A and no anti-B and genomic
analysis revealed an Ax hybrid (A-OIV) allele found in Ax
samples. The other donor sample had a strong anti-A
and no anti-B in the plasma and genomic analysis
revealed the donor to be heterozygous for the B(A)-1
allele. It was concluded that this latter case had the
originally described variant with an A703G mutation as
compared with normal B alleles.9 The RBCs from these
two donors gave the same serologic picture but gave
different serum or plasma grouping and genomic
analysis. The serum grouping makes a clear distinction
between AsubgroupB and B(A) phenotype. The B(A)
phenotype was first described in 1986 in an abstract10
and again in a paper11 by Beck et al. The anti-A clone
(MH04) in the Ortho anti-A reagent that was very
efficient in detecting Ax RBCs was also shown to react
weakly with some group B RBCs.
Group A With Acquired B Antigen 
In 1992, Beck and Kowalski in the communications
section of Immunohematology reported on mono-
clonal anti-B reagents composed of the clone ES4
reacting with RBCs from group A persons because of
the acquired B phenomenon.12 In that same year, there
were two abstracts on this subject.13,14 Five cases in 8
months were observed in the reference laboratory of
Beck at the Community Blood Center in Kansas City.
Previously, this laboratory had only seen two or three
such cases per year. The hospital-based laboratory of
Pedreira et al. identified 13 patients in 9 months. None
had been detected in the 8 months before beginning
the use of a monoclonal anti-B reagent that contained
ES4. It was determined that acidification of the anti-B
reagent to pH 6 would reduce the number of samples
with acquired B antigens that would be detected.
Reagents containing ES4 were manufactured by
Gamma, Immucor, and the former BCA (Biological
Corporation of America,West Chester,PA). Ortho’s anti-
B reagent did not contain this clone and did not react
with RBCs that were group A with acquired B.
The Gamma monoclonal anti-B reagent containing
ES4 was first introduced into blood banking in
November 1990. For two years (1991–1992), six cases
(three per year) of acquired B were investigated by the
Gamma reference laboratory. At that time, Immucor
and BCA also manufactured an anti-B reagent
formulated with ES4. The reagents manufactured by
the three companies varied in pH from pH 7 (Gamma)
to pH 6.5 (Immucor) to pH 6.0 (BCA). In May 1993,
acidified anti-B reagents (pH 6.0) were approved by
FDA for manufacture by both Gamma Biologicals, Inc.,
and Immucor. The Gamma reference laboratory had
eight cases referred in 1993, 1994, and 1995 (2–3 per
year). From 1977 to 1990 (14 years), 28 cases of
acquired B were investigated; again two cases per year.
The Gamma reference laboratory did not see an
increase in the number of acquired B samples because
of the use of monoclonal anti-B reagent containing ES4
from what had been referred to the laboratory before
the introduction of the reagent containing ES4
(personal observations). In April 1996, a monoclonal
anti-B reagent manufactured by Gamma (containing
clone GAMA-110) was introduced to the market; this
clone did not react with acquired B RBCs. Gamma
discontinued manufacturing the anti-B reagent made
from ES4. Immucor still markets an acidified anti-B
reagent made with ES4. It is important to note that
with group AacquiredB there is an ABO discrepancy
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between the forward (RBC) grouping and reverse
(serum) grouping in cases where the anti-B reagent
contained ES4 (except in one rare exception). The
RBCs react strongly with anti-A reagent and react more
weakly with anti-B reagent but the serum or plasma
reacts strongly with B RBCs and weakly or not at all
with A1 RBCs, suggesting group A with unexpected
reactivity of the RBCs with anti-B reagent. Immucor
also now has a tube reagent anti-B made from a clone
that does not react with acquired B RBCs.
These cases are not all inclusive of the types of ABO
discrepancies seen with the use of ABO monoclonal
reagents. However, they give the reader a sense of the
types of unusual samples that have been encountered




After A and B antigens of the ABO blood group
system, D is the most important blood group antigen in
routine blood banking. To enable measures to be taken
to avoid immunization to the D antigen and to assure the
identification of all recipients who should be given only
D– blood, testing for the D antigen is an important
laboratory routine. The D– phenotype occurs with an
incidence of approximately 15 percent in Whites and 9
to 10 percent in Blacks. The term Du was originally
coined in 1946 to describe variable reactivity of certain
bloods with a battery of sera containing saline-reactive
anti-D.15 It has since been replaced by the term“weak D”
to describe forms of the D antigen that may not be
agglutinated directly by anti-D reagents but require an
IAT to detect them.16,17 With the introduction of power-
ful monoclonal anti-D reagents, many bloods formerly
classified as weak D (Du) have been reclassified because
they have been found to show strong direct
agglutination with the newer reagents. Individual mono-
clonal anti-D reagents may differ in regard to their
reactivity with RBCs of this kind. A suitable IgG anti-D
reagent (for use by IAT) is still required to detect some
examples of the weak D phenotype, and the partial D
phenotype known as Category VI. RBCs of apparently
D– donors are generally tested for weak D by converting
negative tests with anti-D reagents to an AHG phase and
then reading the test again. Testing for weak D on
samples from transfusion recipients and prenatal
patients is not required18 and it has been suggested that
the test only be performed on cord bloods of D–
mothers and on samples from blood donors.
Reagents for D typing in the United States currently
consist of four reagents for tube testing and one for
MTS (Ortho) gel cards. Gamma-clone Anti-D and
Immucor Series 4 and 5 Anti-D monoclonal reagents
each contain a blend of an IgM clone and an IgG clone.
Ortho’s tube monoclonal anti-D reagent contains a
blend of an IgM clone and human polyclonal IgG.
Series 4 and 5 of Immucor contain the same IgG clone
and the MTS (Ortho) gel card contains the same IgM
clone used in the Immucor Series 4 (Table 1).
Weak D and Partial D 
Several studies in the United Kingdom, Sweden,
Germany,Canada,and the United States have shown that
there is great variability in reactivity of monoclonal anti-
D reagents with weak D and partial D RBCs because of
multiple factors. In one study by laboratories in the
United Kingdom and Sweden, RBCs of weak D and
partial D phenotypes were tested with 26 IgG and 15
IgM monoclonal anti-Ds. The IgG clone F8D8, used in
the Gamma-clone Anti-D blend reagent and MAD-2 IgM
clone in Ortho’s tube anti-D reagent were part of the
study. Reactivity of monoclonal anti-D is dependent on
antibody concentration and antibody avidity. D antigen
site quantitation was not performed in the study.
However, testing the monoclonal antibodies with RBCs
of the weak D phenotype suggests that site density has a
profound effect on the performance of monoclonal
antibodies in the identification of a D variant, especially
with monoclonal antibodies of low avidity. Some D
variants may be associated with decreased site numbers
and lack of reactivity of monoclonal antibodies with
these RBCs may be because of a quantitative rather than
a qualitative effect.19 Flegel and coworkers in Germany
reported on the molecular basis of weak D.20 Denomme
et al. published studies in Canada with two monoclonal
anti-D reagents, suggesting the importance of testing
samples from prenatal and transfusion recipients with
more than one anti-D reagent.21 They tested 33,864
samples in 18 months and 57 of those demonstrated an
immediate spin discrepancy between two commercial
sources of anti-D reagents. This gave a frequency of 1 in
594 or 0.17 percent. RBCs of the Category DVI type 1
were common and were only superseded by the
frequency of those of weak D, type 1 (n =16).
Jenkins and colleagues in the United States tested
1005 D+ donors on the Olympus PK7200 (Olympus
America, Inc., Melville, NY), using two different anti-D
reagents (one diluted monoclonal blend and one
diluted human polyclonal) and detected four samples
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with RBCs of the weak D phenotype, for an incidence
of 0.4 percent in a primarily White donor population.22
A very comprehensive review of partial D antigens
by Tippett et al. in 1996 showed that monoclonal anti-
D, which provides unlimited supplies of reagents, is
ideal for defining partial D antigens.23 The strength of
partial D antigen varied within all categories and was
most obvious in DVa. Expression of partial D can be
affected by the accompanying gene complex. Partial D
antigen of DVICe appears stronger than that of DVIcE
samples. Variables of antigen (site number, presen-
tation, and accessibility of an epitope) and variables of
monoclonal antibody (immunoglobulin concentration,
immunoglobulin class, and binding constant) affect
reactions of partial D antigens with monoclonal anti-D.
Lomas-Francis (personal communication) found that
the strength of D antigen expression on weak D and
some partial D phenotype RBCs can diminish on
storage. Recently, Judd et al. reported on tests
performed on partial D RBCs with U.S. FDA–licensed
anti-D monoclonal reagents.24 They recommended that
tube D tests should not be converted to weak D tests
at IAT when performing D typing on samples from
pregnant women or potential transfusion recipients.
R0
Har
This is a rare complex that has a weak partial D
(DHAR) antigen, very weak e, no G, and low-incidence
antigens Rh33 and FPTT. In the original study, only 7
percent of polyclonal anti-D reacted with R0
Har RBCs
and R0
Har RBCs were shown to be directly agglutinated
by some saline reactive anti-D.25 Several reports of R0
Har
producing anti-D are in the literature, including a case
of HDN.26–28 The R0
Har haplotype comprises only one
gene; there is no RHD or RHCE but only an RH(CE-D-
CE) hybrid with only exon 5 representing RHD.29 The
majority of IgM but only a few IgG monoclonal anti-D
react with RBCs of the R0
Har phenotype. Although R0
Har
is not a common phenotype, it seems that such RBCs
have been transfused to D– recipients, yet there are no
reports of any adverse effects or stimulation of anti-D
resulting from such transfusions.25 The IgM clones
GAMA-401 (Gamma reagent), TH28 (Immucor Series
5), and MS201 (Immucor Series 4 and MTS gel cards)
will all react with RBCs of the R0
Har phenotype. The
MAD2 clone in the Ortho tube reagent does not.24
Crawford
The low-incidence Rh antigen Crawford was
reported by Cobb in 1980.30 One lot of a U.S.
FDA–licensed polyclonal anti-D reagent, manufactured
by Gamma Biologicals, Inc., was found to contain anti-
Crawford. Although Crawford was not proven to be
part of the Rh blood group system at that time, there
appeared to be a strong association and it was assigned
the number Rh43. That would never happen today!!!
John Moulds always said it would someday be proven
that Crawford was Rh-related and indeed he was
correct. Twenty years later the story continues. While
investigating 27 samples from October 2000 to May
200231 that gave unexplained reactivity with two
commercial monoclonal anti-D reagents from Gamma
Biologicals, Inc., and Dominion Biologicals, Ltd.
(Dartmouth, NS, Canada), testing showed that most, if
not all,of the RBCs were VS+. All 27 samples were from
African American persons, except for one from
Colombia. After seeing these findings, this author had
a revelation!!!  Having been at Gamma when the
Crawford study was initiated and much testing was
performed with the anti-D reagent, a light went on. I
literally ran down the hall to Tom Frame’s office saying
“We need to test Crawford cells”!!  Indeed, of the 27
samples that we were able to test, all reacted with the
original anti-D plus Crawford reagent. We tested 285
samples from D– African American blood donors from
various testing centers (mostly from Tennessee). The
RBCs of two donors were found to react with the
Gamma monoclonal anti-D reagent and the original
anti-D plus Crawford reagent. Interestingly, a total of
500 samples from D– African American blood donors in
Houston did not react.
Samples from several of the donors and patients
that reacted were sent to Dr.Willy Flegel’s laboratory in
Ulm, Germany, for molecular studies. A report of the
findings will appear in Transfusion in 2006.32 It was
shown that Crawford is associated with a novel RHCE
allele, ceCF. The Crawford phenotype is present when
two amino acid substitutions occur within exon 5, Q
(glutamine) at position 233 to E (glutamic acid) and L
(leucine) at position 245 to V (valine); the former
substitution giving rise to several D-specific epitopes
and the latter giving rise to the expression of the VS
antigen on these RBCs. The authors proposed that the
allele be designated ceCF, with CF for Crawford. This
variant allele was reported by Esteban et al. in 2001 in
a pregnant woman from Colombia.33
A third abstract at the same AABB meeting34
reported on a pregnant woman whose RBCs were
originally thought to be R0
Har but were subsequently
shown to be of the Crawford phenotype. Two other
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abstracts pertaining to Crawford presented data on the
molecular background of Crawford occurring with C35
and management of an Rh43 positive donor.36 Westhoff
and coworkers35 confirmed the molecular basis for the
Crawford antigen and its association with r′s observed
in early studies. They raised the possibility that the
RHD-CE-D hybrid, associated with the r′S haplotype,
may contribute to expression of D epitopes in the
Crawford background. Slayten et al.36 described a
donor with a history of typing as D– at one donor
center but on a subsequent donation at another center,
the donor’s RBCs gave questionable D typing results.
The anti-D reagent used at the second center
(monoclonal blend from Gamma containing the IgM
clone GAMMA401) reacted weakly at immediate spin
and did not react at IAT when tested for weak D.
Immucor’s anti-D reagent did not react with this
sample. The donor unit was labeled as D+. The donor
was notified of the discrepancy and was told that if the
donor was to require a blood transfusion, only D–
blood should be transfused. To quote the authors,“The
coordination and communication of the donor typing
results from the centralized donor testing laboratory
and the regional blood center were critical for the
correct labeling of the donated products and the
management of the donor.”
Anti-C
The monoclonal anti-C reagents produced by
Gamma, Immucor, and Ortho are all made using the
same clone (MS24). The interpretation of test results
section of the Gamma package insert for Anti-C
(Monoclonal) Gamma-clone (March 2004) states that
“The C antigen produced by certain Rh genes may give
weaker reactions with Anti-C than is seen with the cells
selected as controls. In particular, weaker reactions
may be observed (even after incubation of the test)
with the C antigen that is a product of r′s (Cces), RZ
(DCE), and ry (CE) genes than the C that is a product
of R1 (DCe) and r′(Ce).” There have been occasions
when the Gamma-clone Anti-C reagent reacted weakly
and the Immucor and Ortho anti-C reagents did not
react. The difference in reactivity between these
reagents is because of the second cause of discrepant
reactions with monoclonal reagents made from the
same clone: differences in the diluents used by the
three manufacturers and in potency of the final
product.We encountered two situations with r′s and RN
(Rh32).
Cces (r′s)
RBCs of this phenotype possess a weak C antigen
and the low-incidence antigen VS. In Blacks, the VS
antigen occurs in 26 to 40 percent; in other
populations, it occurs in less than 0.01 percent.37
Recently, the molecular background of VS and weak
expression of C in Blacks was published by Faas et al.
in the Netherlands.38 They postulated that a hybrid D-
CE-D transcript, containing exon 4, 5, 6, 7, and
(probably) 8 from the RHCE gene, is responsible for the
weak expression of C in the three donors studied. “The
hybrid gene carried a Leu62Phe substitution, as well as
the Leu245Val substitution responsible for VS. The
gene most probably cosegregates with a C allele
encoding Cys 16 (normally encoded only by the C
allele) and Val 245 (responsible for VS antigenicity
when encoded by the RHCE gene). This explains the
combination of weak expression of C and VS positivity
that is frequently found in Blacks.”
In another report,39 Daniels et al. studied RBCs from
100 Black South Africans and 43 Black persons from
the Netherlands. The respective frequencies of all VS+
and of VS+V– (r′s) phenotypes were 43 percent and 9
percent in the South Africans and 49 percent and 12
percent in the Dutch donors. All VS+ donors had G733
(Val245) but six with G733 were VS– (four V+w, two
V–). They concluded that it is likely that anti-VS and
anti-V recognize the conformational changes created
by Val245 but anti-V is sensitive to additional
conformational changes created by Cys336.
RN (Rh32) 
The RBCs of a Gamma employee from Puerto Rico
(Puerto Rican and Black ethnicity) phenotyped as
D+C+E–c+e+ (probable Rh genotype R1r). However,
one of the technologists in the reagent manufacturing
department found that his RBCs gave a weaker reaction
with the Gamma monoclonal anti-C reagent in titration
studies than did another RBC of the same phenotype.
The RBCs also did not react with Immucor and Ortho
anti-C reagents. The RBCs did not react with anti-VS
but reacted with two examples of anti-Rh32.
Rosenfield et al.40 first described the RN gene in a
Black family as producing a normal expression of D and
traces of C and e, but in some studies, RN has been
shown to produce elevated D antigen expression. It
has been estimated that Rh32 is present on RBCs of 1
percent of African Americans. Numerous homozygotes
have been found because of anti-Rh46 in their serum
and others because of weak C and e antigens.41
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Anti-E
All three commercial anti-E tube reagents and the
MTS gel card anti-E available in the United States are
comprised of different clones. In the limitations
section of the package inserts (Gamma Biologicals,
Inc., February 2004; Ortho-Clinical Diagnostics, March
1999), the manufacturers state that variant E antigens,
such as Ew, may not react with these reagents. One
manufacturer (Gamma, February 2004) goes on to say
“this limitation is not unique to monoclonal reagents.
It applies equally to some polyclonal Anti-E products.”
The Gamma reference laboratory investigated a donor
sample in 2003 that did not react with all three
monoclonal anti-E reagents but did react with three
human polyclonal anti-E reagents. An Ew+ RBC gave the
same pattern of reactivity but the RBCs of the donor
did not react with anti-Ew and must express a different
E variant. Molecular studies have not been performed
on samples from the donor.
Ew
The low-frequency Rh antigen Ew was first described
by Greenwalt and Sanger in 1955,42 when an antibody in
the serum of a White woman caused HDN. Several other
examples followed in the 1960s and 1970s.
E variants
Lubenko and colleagues43 reported on a new
qualitative variant of E different from Eu (quantitative
variant), depressed (C)D(E) gene complex and
qualitative variant Ew and ‘partial’ antigen ET. The RBCs
of their proposita were agglutinated by eight of 12
polyclonal sera, were weakly agglutinated by two, and
not agglutinated by the remaining two. One of three
monoclonal anti-E reagents tested by flow cytometry
did not react, a second bound strongly, and the third
bound weakly. Noizat-Pirenne et al.44 reported in 1998
on the molecular basis of qualitative E variants and 
the same author and other colleagues reported in 1999
on the molecular basis of category EIV variant
phenotype.45
The first group reported that the E antigen is
composed of at least 4 epitopes, proline 226 being
necessary but not sufficient for full expression of E
antigen. In the second report, they confirmed the
heterogeneous molecular background responsible for
the E epitope alterations and defined category EIV
molecular background. As compared to category EI,
EII, and EIII, category EIV appears to possess all 4
epitopes although the expression of some appears to
be suppressed. The decreased expression of some E
epitopes in category EIV can be explained by confor-
mational modifications induced by the intracellular
amino acid substitution at position 201. As a result,
categories EI, EII, and EIII could be considered as
partial E phenotypes whereas category EIV could be
considered as a weak E phenotype. More recently
(2001), a study was undertaken in Japan46 that tested
monoclonal anti-E with 15 E variant samples. These 15
E variant samples were found in screening 140,723
Japanese blood donors for an incidence of 0.011
percent. A new variant (RHEKH) was found. The
variants were subdivided into three types; EFM, EKH,
and EKK.
Anti-c 
The three anti-c tube reagents in the United States
contain different clones but the clone used by
Immucor (MS33) is also used in the MTS gel card. In
the limitations section of the Gamma package insert for
Anti-c (Monoclonal) Gamma-clone (June 2005), it is
stated “The monoclonal antibody that is the active
ingredient of this product has been observed to show
negative reactions with the Rh26 antigen, which is a
component that is absent from a rare phenotype
reported as representing a variant or partial form of the
c antigen. This may introduce discrepant results
between those observed with this product and other
sources of anti-c. Cells lacking Rh26 may react with
some monoclonal anti-c reagents. They can also be
expected to show reactivity with most polyclonal anti-
c reagents, albeit more weakly than those possessing a
normally expressed c antigen. The uncommon
phenotype that includes a weak c antigen and no Rh26
may show variable incidence in different populations.”
Rh26 was first reported by Huestis et al. in 1964.47 The
patient’s RBCs typed as probable Rh genotype R1R1 (c–)
and the serum contained anti-c but the antibody did
not react with the RBCs of an Italian donor who typed
c+ with anti-c reagents.
The Gamma reference laboratory investigated a
sample from a woman whose RBCs were determined
to be Rh:-26 when they typed c+ but her serum
contained alloanti-c. Her RBCs did not react with the
original anti-Rh26 serum.48 More recently, it was shown
that these RBCs do not react with the Gamma
monoclonal anti-c reagent (clone 951) but that they do
react with Immucor (clone MS33) and Ortho (clone
MS42) monoclonal anti-c reagents. These anti-c clones
were part of a study in 1997 in the Netherlands.49
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Anti-e  
The anti-e reagent of Gamma contains three clones
(MS16, MS21, and MS63). One of the clones (MS16) is
used as the single clone for the Immucor and Ortho
anti-e tube reagents. The MTS gel card uses the same
three clones that are in the Gamma tube reagent. Most
discrepant reactions will be caused by those samples
that react with the Gamma anti-e reagent but do not
react with Immucor and Ortho tube anti-e reagents. The
limitations section of the Immucor package insert for
Anti-C,Anti-E,Anti-c,Anti-e Series 1 (11/01) states “The e
antigen may be only weakly expressed on the RBCs of
some Blacks and such RBCs may react weakly with anti-
e. Some hrS– or hrB– RBCs may not react with anti-e.
Anti-e may give slightly weaker reactions in the absence
of the C antigen.”50 Three other publications can be
consulted for more information on e variants.51–53 The
Gamma reference laboratory encountered one sample
that did not react with Gamma anti-e blended reagent
but did react with the Immucor and Ortho anti-e
reagents that contain only one clone (MS16). When the
three clones in the Gamma reagent were tested
separately, the MS16 clone did react with the RBCs but
the other two clones did not. When MS16 was blended
with the other two clones to make the Gamma anti-e
reagent, the potency of the clone was weakened,
causing the reagent to not react with what appeared to
be a different e variant. Molecular studies have not been
performed on this sample.
Anti-K  
Immucor and Gamma manufactured monoclonal
anti-K reagents that contain the same clone (MS56).
The RBCs of a donor that originally typed as K– with a
monoclonal anti-K reagent were found to react with a
human polyclonal anti-K reagent. Serologic studies
indicated that the RBCs from the donor had weakened
or altered expression of K antigen. Molecular analysis
has not been completed. Skradski et al.54 reported in
1994 on a K variant and summarized previous reports
of weakened or variant expression of K. Poole and
coworkers55 reported on serologic and molecular
studies on the RBCs of two Swiss blood donors. Their
RBCs reacted with various anti-K but did not react with
monoclonal anti-K MS56 clone.
Anti-M and Anti-N  
Gamma and Immucor both have monoclonal anti-M
reagents and use different clones. The Gamma clone
(M2A1) is IgG1 and the Immucor clone (F23) is IgM.
In the limitations section of the Gamma package insert
for Anti-M (Murine Monoclonal) Anti-N (Murine
Monoclonal) Gamma-clone, it states “Variant
sialoglycoproteins exist that may, on relatively
uncommon occasions, cause aberrant reactions when
testing human red blood cells with Anti-M and Anti-N
reagents (and also with Anti-S and Anti-s). The presence
of an N-like antigen (‘N’) on glycophorin B (the S/s
sialoglycoprotein) is well known to be the cause of
weak reactivity between N– cells and Anti-N reagents,
which may be mistakenly attributed to the presence of
the N antigen itself…when the level of glycophorin B
is increased, as occurs in the case of some hybrid
sialoglycoproteins, the resulting enhanced expression
of ‘N’ may for all practical purposes be
indistinguishable from normal N. Such enhanced
expression of ’N’ has been noted as a feature that
accompanies the low-incidence antigen Dantu,and also
occurs with cells classified as Mi III in the Miltenberger
subsystem.”56
A different type of situation arose when the
Gamma reference laboratory examined the RBCs of a 1-
year-old child whose serum contained anti-M but
whose RBCs reacted with the Gamma human
polyclonal anti-M reagent and did not react with the
Gamma monoclonal anti-M reagent. In this case, the
monoclonal reagent gave the result consistent with the
antibody in the serum. It turned out that the Gamma
human polyclonal anti-M reagent contained anti-Tm,
which is directed at a low-incidence antigen associated
with the MNS blood group system. The human anti-M
reagent is tested at 4°C and the anti-Tm in the reagent
was very weak. It is well known that manufacturers
cannot eliminate the possibility that human polyclonal
reagents might contain antibodies directed at low-
incidence antigens and testing on the reagents is only
done with common antigens with a frequency of 1
percent or greater; i.e., CW, Kpa, Jsa, etc.
Anti-Lea and Anti-Leb
Immucor and Ortho use the same clones for their
anti-Lea and anti-Leb reagents. These reagents are very
temperature sensitive and the manufacturers’ package
inserts (directions for use) should be followed closely
as to optimum temperature and incubation time for
each reagent. Gamma uses different clones.
A weak positive reaction with a monoclonal Anti-Leb
reagent and Le(a+) RBCs of any ABO group should not
be considered negative as this may represent the
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Le(a+b+) phenotype. The evaluation of these unusual
reactions may require secretor studies. The Leb reaction
of Le(a+b+) RBCs may range from very weak to strong.
The Le(a+b+) phenotype is common in Orientals and
Polynesians but uncommon in Europeans. It occurs in
persons of African origin but there is no data on the
incidence. The Le(a+b+) phenotype has been
established by serologic, immunochemical, and genetic
means.57 The strength of the Lewis antigens may be
diminished during pregnancy and with newborns58 or
in patients with cancer and other diseases.59
Anti-P1  
Gamma manufactures the only FDA-licensed
monoclonal anti-P1 reagent, using clone OSK17. In the
interpretation of test results in the package insert for
Anti-P1 (Murine Monoclonal) Gamma-clone (March
2003), there is a special note that states “The
monoclonal Anti-P1 reagent is somewhat more potent
than most polyclonal reagents of the same specificity.
This may result in an unexpected positive reaction
when the cells being tested have a comparatively weak
P1 antigen that is not being reliably detected by
polyclonal reagents.”60,61
Monoclonal Antihuman Globulin Reagents
Anti-IgG  
Gamma manufactures a monoclonal anti-IgG
reagent using clone 16H8. This clone is also used in the
polyspecific AHG reagent along with a monoclonal
anti-C3b,-C3d. Immucor no longer makes a rabbit anti-
IgG reagent and Ortho manufac-tures a rabbit tube anti-
IgG reagent. The Ortho polyspecific AHG reagent is a
blend of rabbit anti-IgG and monoclonal anti-C3. The
anti-IgG clone 16H8 in the Gamma reagents reacts with
an epitope on the CH3 domain of the Fc region of
human IgG. Examples of pure IgG4 subclass antibodies
may not be detected by this reagent. Pure IgG4
antibodies are very uncommon. They have not been
reported to cause hemolytic transfusion reactions or
HDN. Autoanti-JMH is the one most often seen. All
except five of seven JMH antibodies,one of one anti-Rg,
and two of nine Yta antibodies were detected by the
monoclonal AHG reagent.62
Bell and Johnson reported on the use of the
monoclonal anti-IgG and PEG to reduce the detection
of “high-titer, low-avidity” antibodies.63
Anti-C3b,-C3d  
Gamma and Ortho manufacture monoclonal anti-
complement reagents using different clones; Immucor
does not make this reagent. In the Gamma package
insert (February 2005) under the test method section
for this reagent there is a statement “Note: Weak anti-
complement reactions are often enhanced if the
washed cells and Anti-C3b,-C3d are incubated for a
short period before centrifugation. A delay of five
minutes before proceeding to Step 5 may improve the
detectability of a weak C3 coating, although the greater
potency of this Anti-C3 reagent over conventional ones
generally results in better reactivity at the immediate-
spin phase.”64
Additional Reading  
Three other references on monoclonal antibodies
and unusual samples can be consulted for more
extensive information. The wonderful, heavy, blue
book Applied Blood Group Serology, Fourth Edition,
by Peter D. Issitt and David J. Anstee, has a wealth of
information on serologic and molecular findings with
monoclonal antibodies.65 Unfortunately, I have heard
that it will not be printed again but fortunately that
means we can copy it for our own use!  Good luck
copying all those pages (1208 in all)!  Connie Westhoff
wrote an excellent review of the Rh blood group
system and summarized serologic and molecular
analysis of weak D, partial D, weak C, e variants, etc.66
Her list of references includes numerous recent
publications on molecular analysis of Rh variants. And,
in Immunohematology, she wrote a very compre-
hensive and practical review of the Rh blood group D
antigen.67 And, finally, I wrote an article for Advance
magazine on monoclonal antibodies as blood bank
reagents with special reference to ABO, D, C, and e, and
monoclonal AHG reagents.68
Summary  
In this review I have attempted to give a summary
of recent serologic and molecular studies on unusual
samples detected when using monoclonal antibodies
as blood bank reagents. It was not possible to list every
publication but I tried to list recent papers, which
often referred to earlier papers that laid the foundation
for work being performed today. In general, reagents
made with different monoclonal antibodies give
reactions that are the same as or similar to reagents
manufactured from human, animal, or lectin (seed)
source material. It is when unusual or rare samples are
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encountered that users of monoclonal reagents need to
know how each reagent from different sources or
manufacturers performs. I also selected the samples
that most often gave discrepant results with
monoclonal reagents. There are many others that I
have not covered and the interested reader is directed
to the various references for further information.
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